ARV-393 for relapsed or refractory non-Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new oral medication (ARV-393) for people with certain types of non-Hodgkin lymphoma that have returned or not responded to previous treatments. The drug is designed to target a protein inside cancer cells to make them stop growing and die.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments.
- You must have at least one lymphoma spot that can be measured on a scan.
- You must be relatively well and able to care for yourself (ECOG score of 0 or 1; some exceptions for certain patients).
- Your bone marrow, kidney, and liver function need to be adequate.
- You cannot have had a stem cell transplant from someone else or CAR-T therapy within the last 60 days.
- You cannot have had a heart attack, heart failure, serious irregular heartbeat, or certain other heart problems in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
This trial tests a combination of five drugs (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) for patients with angioimmunoblastic T-cell lymphoma (AITL) that has come back or not responded to previous treatment. The goal is to see if this combination can shrink tumors or stop the disease from growing.
This early trial tests a new type of cell therapy (called ARI0003) for aggressive B-cell lymphomas that have not responded to standard treatments or have relapsed. The therapy uses your own immune cells to fight the cancer, and it may offer a new option when other treatments have not worked well.
This trial tests a new combination of two medicines, pembrolizumab and ATRA (a form of vitamin A), for people with certain lymphomas that have come back or stopped responding to earlier treatments. The goal is to see if the combination can help the immune system fight the cancer more effectively.
This trial tests an experimental drug, SP-3164, for people with certain types of non-Hodgkin's lymphoma that have come back or not responded to prior treatments. The goal is to see if the drug can help shrink or control the cancer.
This study tests an experimental drug (GSK5926371) for people with a type of lymphoma (B-cell NHL) that has come back or not responded to earlier treatments. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Hear when a new Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.